

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

**CHANGE OF JOINT COMPANY SECRETARY,
AUTHORISED REPRESENTATIVE AND PROCESS AGENT
AND
WAIVER FROM STRICT COMPLIANCE WITH
RULES 3.28 AND 8.17 OF THE LISTING RULES**

**CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED
REPRESENTATIVE AND PROCESS AGENT**

The Board of Directors (the “**Board**”) of Suzhou Basecare Medical Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Yim Lok Kwan (“**Mr. Yim**”) has tendered his resignation as (i) the joint company secretary of the Company (the “**Joint Company Secretary(ies)**”); (ii) an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and (iii) an authorised representative of the Company under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) for the acceptance of service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) with effect from August 29, 2022.

Mr. Yim has confirmed that he has no disagreement with the Board and that there are no circumstances relating to his resignation which needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board further announces that Mr. Chung Ming Fai (“**Mr. Chung**”) has been appointed as a Joint Company Secretary, the Authorised Representative and the Process Agent with effect from August 29, 2022.

The biographical details of Mr. Chung and the other Joint Company Secretary, Ms. Wang Yan (“**Ms. Wang**”), are set out as follows:

Mr. Chung is a vice president of SWCS Corporate Services Group (Hong Kong) Limited and has over 17 years of experience in corporate secretary, mergers and acquisitions, financial reporting and auditing. Mr. Chung is currently a fellow of the Hong Kong Institute of Certified Public Accountants and a member of CPA Australia. He obtained his bachelor’s degree in commerce from the Australian National University.

Ms. Wang was appointed as our chief financial officer with effect from March 18, 2022 and our Joint Company Secretary on April 19, 2022. Ms. Wang is responsible for the finance, budgeting, internal control and investor relationship of our Group.

Prior to joining our Group, she served as the chief financial officer of PreAngel Fund (上海荷多投資管理有限公司) from April 2021 to March 2022. From September 2019 to March 2021, she served as the chief financial officer of Shanghai MJstyle Group (上海覓尚服飾有限公司). From December 2016 to September 2018, she served as the chief financial officer of Rici Healthcare Holdings Limited (瑞慈醫療服務控股有限公司) (stock code: 01526.HK). From October 2015 to November 2016, she served as the chief financial officer of Shanghai Smart Arena Network Technology Co., Ltd. (上海慧體網絡科技有限公司). From July 2010 to September 2015, she served as the financial director and enterprise resource planning director of Touch Media Group (觸動傳媒集團). From June 2006 to June 2010, she served as a senior internal auditing manager of Shanghai The 9 Computer Consulting Co., Ltd. (上海第九城市計算機諮詢有限公司).

Ms. Wang received her bachelor’s degree in economics from Fudan University (復旦大學) in China. Ms. Wang is a member of the Chinese Institute of Certified Public Accountants, a certified internal auditor granted by the China Institute of Internal Audit and a Middle-Level Accountant granted by the Ministry of Finance of the People’s Republic of China.

The Board is of the view that, having regard to Mr. Chung’s relevant experience, Mr. Chung will be able to advise both Ms. Wang and the Company on the relevant requirements of the Listing Rules as well as other applicable laws and regulations. Mr. Chung will assist Ms. Wang to enable her to discharge her duties and responsibilities as a Joint Company Secretary of the Company. Mr. Chung is considered a suitable candidate to act as the Joint Company Secretary.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Reference is made to the waiver (the “**Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in respect of the eligibility of Ms. Wang to act as a Joint Company Secretary for a three-year period from the date of Ms. Wang’s appointment as a Joint Company Secretary (i.e. April 19, 2022) (the “**Waiver Period**”), on the condition that Ms. Wang would be assisted by Mr. Yim, who possesses the qualifications required under Rule 3.28 of the Listing Rules, during the Waiver Period. Relevant details of the Waiver were disclosed in the announcements of the Company dated March 11, 2022 and April 19, 2022.

Given the condition of the Waiver could no longer be fulfilled following the resignation of Mr. Yim, the Company has applied to the Stock Exchange and has been granted with a new waiver (the “**New Waiver**”) by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for the remaining period of the Waiver Period (the “**Remaining Waiver Period**”) in relation to the eligibility of Ms. Wang to act as a Joint Company Secretary, on the conditions that:

- (i) Ms. Wang must be assisted by Mr. Chung during the Remaining Waiver Period; and
- (ii) the New Waiver can be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Remaining Waiver Period, the Company must demonstrate and seek the Stock Exchange’s confirmation that Ms. Wang, having had the benefit of Mr. Chung’s assistance during the Remaining Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The Board would like to take this opportunity to express its gratitude to Mr. Yim for his contribution to the Company during his tenure of service and welcome Mr. Chung on his new appointment.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, August 29, 2022

As of the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. YANG Ying as executive directors; Mr. XU Wenbo, Mr. ZHANG Jiecheng and Mr. WANG Weipeng as non-executive directors; Dr. KANG Xixiong, Dr. HUANG Taosheng and Mr. CHAU Kwok Keung as independent non-executive directors.